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Preface 
Our research is based on patients with hereditary ataxia. In Norway patients referred to our 
neurological clinics are older than 16 years and this work is therefore based on work with 
adult patients. In addition I have most of the time worked with the dominant forms as this 
thesis will be colored of. Paper 1 was a prevalence study on hereditary ataxias and in this 
study we included children.  All results from patients younger than 16 years were therefore 
based upon collaboration with pediatricians. I have not examined the children in this study 
myself. Also the included work on A-T in this paper was done by Asbjørg Stray-Pedersen and 
based on the work she did during her thesis on these disorders. In the same paper the HSP part 
has already been defended by Anne Kjersti Erichsen in 2009 and this work is therefore not a 
part of my thesis. 
Many recessive disorders have ataxia as an additional feature and the same goes for 
mitochondrial disorders. Only recessive disorders with ataxia as a main feature are included in 
my work.   
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Abbreviations 
ADCA-Autosomal Dominant Cerebellar Ataxia 
ARCA-Autosomal Recessive Cerebellar Ataxia 
FRDA-Friedreich’s Ataxia 
SCA-SpinoCerebellar Ataxia 
AVED-Ataxia with Vitamin E Deficiency 
AOA1-Ataxia with Oculomotor Apraxia type 1 
SCAR1-SpinoCerebellarAtaxia Recessive type 1/AOA2-Ataxia with Oculomotor Apraxia 
type 2 
A-T-Ataxia-Telangiectasia 
HSP-Hereditary Spastic Paraparesis 
MRI-Magnetic Resonance Imaging 
MSA-c-Multippel System Atrophy Cerebellum 
DRPLA-Dentato-Rubral-Pallido-Luysian Atrophy 
HA-Hereditary Ataxia 
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Introduction and background 
Definition  
Ataxia means lack of order or in-coordination. It is one of the most common neurological 
symptoms and also described by J.M. Charcot (1825-1893) and his colleges at Hôpital de la 
Salpêtrière, Paris in the 17.century (Figure 1). 
Ataxia may affect the arms, legs, truncus, speech, throat and eye movements. Ataxia can 
occur in all kind of disorders affecting the cerebellum and its pathways, the dorsal columns 
and the vestibular system. Four main groups of disorders can give the symptom ataxia: 
1. Hereditary ataxias 
2. Secondary ataxias 
3. Sporadic ataxias 
4. Mitochondrial disorders 
 
Figure 1.  Jean Martin Charcot, the first professor in neurology working at Hôpital de la 
Salpêtrière in the late 17.century. The entrance of the Hôpital de la Salpêtrière in 2009. 
 
Hereditary ataxias  
The hereditary ataxias (HA) are a group of rare monogenetic neurodegenerative disorders 
characterized by slowly progressive incoordination of gait, limbs, speech and eye movements 
which are inherited in an autosomal recessive, dominant or X-linked manner also called 
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autosomal recessive cerebellar ataxia (ARCA), autosomal dominant cerebellar ataxia (ADCA) 
or X-linked ataxias. Together with hereditary spastic paraplegias they are often called 
hereditary spinocerebellar disorders.  
The hereditary ataxias have been difficult to classify and attempts to classify them have 
historically been based on clinical descriptions, neuropathological descriptions or image-
forming techniques. At a time there were almost as many different types of hereditary ataxias 
as authors publishing them. The first neurologist who made a systematic classification system 
of hereditary ataxia was Anita Harding (1-4). She classified the ADCA clinically into four 
main groups due to additional features (Table 1) (3).   
 
Table 1. Harding’s classification system for ADCA, based on clinical features in addition to 
the cerebellar ataxia 
ADCA 
type Clinical features in addition to the cerebellar symptoms 
ADCA1 Ophtalmoplegia/optic atrophy/dementia/extrapyramidal signs and symptoms 
ADCA2 Pigmentary retinopathy and/or opthalmoplegia/extrapyramidal features 
ADCA3 Pure, often late onset (over 50 years) 
ADCA4  Myoclonus, deafness 
ADCA-autosomal dominant cerebellar ataxia 
With increased knowledge of molecular diagnoses from the early nineteen-ninety the 
classification changed from clinical descriptions to exact genetic diagnoses. A genetic 
classification system is therefore nowadays common and accepted. This means they are 
classified after main mode of inheritance and then if possible after the gene/locus causing the 
disorder. ADCA is commonly denoted SpinoCerebellar Ataxia and then numbered 
chronologically following publication date (SCA1-36). The same system is being proposed 
with ARCA, SpinoCerebellar Ataxia Recessive SCAR1-10 or ARCA1-2, but unfortunately 
this easily understood classification system is not in use and incomplete (5-17). For the 
recessive ataxias it is today more common to use the well-established names after main 
clinical feature, protein dysfunction, geographical origin or after the scientist who first 
described the phenotype, e.g.; Friedreich’s ataxia, ataxia with oculomotor apraxia (AOA1 and 
2), ataxia telangiectasia (A-T), ataxia with vitamin E deficiency (AVED) and autosomal 
dominant spastic ataxia of Charlevoix-Saguenay (ARSACS).  
Supplementary investigations with neuroimaging, neurophysiologic investigations, genetic 
tests and biomarkers are often needed to exclude other causes of ataxia and in order to give an 
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exact genetic diagnosis. Main diagnoses to be considered before a hereditary ataxia diagnosis 
can be made are listed in Table 2 and discussed briefly in the chapter non-hereditary 
neurodegenerative ataxias (8;9;11-13;18-26) .  
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Table 2. Main diagnoses to be considered when investigating a patient with progressive 
ataxia 
Group of disorder Disorders affecting cerebellum and/ 
or its pathways 
Clinical clues 
Acquired ataxias/ 
secondary ataxias 
 
Paraneoplastic disorders, multiple sclerosis, 
vascular malformations, ischemia, bleeding, 
infections (i.e. HIV, syphilis, borrelia etc.), 
primary or metastatic tumors, toxic 
substances (alcohol, phenytoin), vitamin 
deficiencies (B12, vitamin E) 
Additional investigation with brain MRI, 
lumbar puncture, blood samples will give 
important clues to the diagnoses. No 
typical family history. May not be 
progressive. 
Non-hereditary 
neurodegenerative 
ataxias 
 
Sporadic ataxia, MSA-c Late onset (>50 years), MSA-c often with 
autonomic symptoms. No family history. 
Progressive. 
Primary hereditary 
ataxias 
Autosomal recessive, dominant and X- 
linked hereditary ataxias 
Other family members affected with a 
similar disorder, autosomal recessive 
forms have often earlier onset compared 
to the dominant forms. Progressive or 
episodic forms. 
Mitochondrial 
disorders* 
POLG related disorders (i.e.: SCAE, SANDO, 
MEMSA), 
IOSCA, MERRF, NARP 
Kearne-Sayre syndrome 
Maternally inherited Leigh syndrome 
Leigh syndrome, LBSL 
 
Ataxia is seen in many mitochondrial 
disorders. Mitochondrial disorders have to 
be considered when ataxia is accompanied 
by other symptoms and signs. SCAE is a 
frequent MIRAS in Norway. These 
disorders are progressive, often multi-
system disorders /giving other 
neurological manifestations in addition to 
ataxia.  
Metabolic 
disorders with 
ataxia 
Disorders affecting the ammonium, amino 
acid, pyruvate, lactate or the fatty acid 
metabolism, such as; GM1 and GM2 
gangliosidosis, Niemann-Pick, Refsums 
disease, abetalipoptroteinemias, 
acanthocytosis, Cerebrotendinous 
Xanthomatosis 
Often early onset, ataxia is often an 
additional symptom and not the only 
symptom. The progression can be more 
aggressive compared to the primary 
hereditary ataxias.  
*- only mitochondrial disorders were ataxia is a common feature is mentioned. 
MSA-c= multiple system atrophy cerebellum, MIRAS= mitochondrial recessive ataxia syndrome, SCAE=spinocerebellar 
ataxia with epilepsy, SANDO=sensory ataxia neuropathy dysarthria and ophthalmoplegia, MEMSA=Myoclonic epilepsy 
myopathy sensory ataxia,  IOSCA= infantile-onset spinocerebellar ataxia, MERRF= myoclonic epilepsy with ragged red 
fibers,  NARP=neuropathy-ataxia retinitis pigmentosa syndrome, LBSL=leucencephalopathy with brainstem and spinal 
cord involvement, dilated cardiomyopathy with ataxia, GM gangliosidosis-lysosomal storage disorders characterized by 
generalized accumulation of gangliosidosis due to deficiency of different enzymes 
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Non-hereditary neurodegenerative ataxias/sporadic ataxia 
and isolated cases 
Many patients have progressive balance difficulties, dysarthria, dysphagia and visual 
symptoms with features of a cerebellar disease without other family members having the same 
symptoms (19;27). Isolated subjects can hide a monogenetic disorder, because no family 
members report the same disorder, due to complicating factors to the inheritance pattern listed 
in Table 3. As we learn more about the inheritance patterns for monogenetic disorders, it is 
becoming clear that exceptions to the simple Mendelian rules of inheritance are relatively 
common. Sporadic ataxia is often defined as a non-genetic ataxia, but there is no distinct 
definition for sporadic ataxia in the literature. Some publications include MSA, late onset 
idiopathic cerebellar ataxias and secondary ataxias (27). Others use more stringent criteria 
with only adult onset sporadic ataxia with unknown etiology and MSA-c (19), as we do in our 
work. The sporadic ataxias can be divided in pure or complex forms. Pure forms, known as 
late onset idiopathic cerebellar ataxias, have mainly pure cerebellar symptoms and signs. The 
complex form, known as MSA-c, may in addition to the cerebellar signs have brainstem, 
Parkinson-like and autonomic symptoms. Disability may be greater and the disease progress 
faster with the MSA-c. Brain imaging typically shows cerebellar atrophy in sporadic ataxia 
with or without atrophy of the brainstem without other findings for a secondary ataxia.  
The etiology of these disorders is unknown, but also among sporadic ataxia there will be 
hidden isolated subjects with hereditary ataxia, because molecular testing for all HA genes 
has until today not been feasible due to the high expenses and the time-consuming process it 
is to sequence all genes. 
 
Table 3. A list over complicating factors to the general inheritance patterns 
 
 
  
1. Incomplete penetrance/age-dependent penetrance 
2. Small family size, early death of an affected parent, adoption or not reported 
correct biological father may hide the inheritance pattern in the family 
3. Unstable alleles/ anticipation  
4. De novo mutation 
5. Variable expressivity 
6. Sex related genetic effects (i.e. imprinting) 
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Epidemiology 
Previous studies (Table 4) estimate the prevalence of hereditary ataxia between 1.6-18/100 
000, ADCA between 1.6-3.7/100 000 with spinocerebellar ataxia (SCA) 1, 2 and 3 as the 
most common subtypes worldwide (6;27-43). Figure 2 shows the distribution of the most 
common SCA worldwide (15;25).  There are less data on the prevalence of ARCA, which is 
estimated to be between 1/100 000 to 4.7/100 000 (28-31;35;37;44). Friedreich’s ataxia 
(FRDA) is reported to be the most prevalent recessive form in central Europe, however with 
an uneven distribution worldwide. Its estimated prevalence ranges from being non-existent to 
4.7/100,000 (2;31;32;35;36;39;44-48). Ataxia telangiectasia (A-T) is estimated as high as 1 
per 40.000-100.000 live births in the USA (49) and is the only form of hereditary ataxia 
recently genetically described in Norway (50-52). Ataxia with vitamin E deficiency (AVED) 
and ataxia with ocular apraxia type 1 (AOA1) and type 2 (AOA2) are rare and to date the 
prevalence is unknown (8;39;53). 
One of the first epidemiological studies on hereditary ataxias was conducted by a Norwegian 
neurologist, Håvard Skre, on the west coast of Norway in 1974 and 1975. He estimated, on 
clinical criteria, the prevalence of ADCA at 3.2/100 000, and ARCA at 3.0/100 000 (30;31). 
No studies have been performed since then, even though we today have molecular diagnostics 
and a new classification system for these disorders. Our neighbour countries have published 
data on SCA8 (Finland) and SCA6 (Sweden) (46;54;55).  
 
Despite all these studies there are huge differences in prevalence of hereditary ataxias 
worldwide and the occurrence of the different forms. This is mainly due to differences in 
methods, inclusions criteria and founder effects. SCA8 in Finland, SCA3 in Portugal, AVED 
in Italy and northern Africa and ARSACS in Canada are all good examples of founder effects 
in these countries (25;55-58). No studies of the occurrences of the different forms existed 
from Norway before we started our work. 
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Table 4. Prevalence studies previous to our study 
        
Author  Country  Published year Population Included diagnoses All diagnoses HA ADCA ARCA/FRDA 
Leone  Italy 1990 3 617 915 FRDA 1.2 NA NA NA /1.2 
Polo  Spain 1991 510 000 HSP,HA,spo 20.2 8.2 1.2 7.0/4.7 
Filla  Italy 1992 335 211 HSP and HA 7.5 4.8 0 4.8/2.1 
Hirayama  Japan 1994 123 000 000 HA,spo,MSA,HSP 4.53 1.5 NA NA/0.1 
Lopez-Arlandis  Spain 1995 3 898 241 FRDA 3.98** NA NA 3.98** 
Silva  Portugal 1997 1 600 000 HSP,HA 6.4 4.4 0.8 2.4/2.4 
Mori  Japan 2001 613 439 HA, spo,MSA,HSP 17.8 NA 3.36¤ NA/0 
van de Warrenburg  Netherland 2002 15 863 950 ADCA 3.0* NA 3.0* NA 
Zhao  Singapore 2002 3 500 000 ADCA ¤¤ NA 3.7 NA 
Juvonen  Finland 2002 5 180 000 FRDA *** NA NA *** 
Sasaki Japan 2003 NA HA,spo,MSA,HSP 15.68 NA NA NA/0 
Zortea  Italy 2004 845 203 HA 9.33 9.3 2.4± NA/0.6 
Muzaimi  Wales 2004 570 000 HA, spo>20years 10.2 1.8 NA NA 
Infante  Spain 2005 527 000 ADCA 1.6 NA 1.6 NA 
Tsuji Japan 2007 NA HA,spo,MSA,HSP 18.5 30.3%† 27.0%† 1.8%† 
The table shows prevalence studies published from 1990 to 2007. Prevalence studies with a population less than 
200 000 are not included in this table. *extrapolation, **Hardy Weinberg's principle, ***carrier frequency 1/500. 
7 subjects/5.18 mill, ¤SCA1,3,6 and DRPLA, ¤¤1/27.000, ± SCA 1,2,3,6,7,8,12,17,DRPLA , †% of the 
prevalence for all included diagnosis  
ADCA=autosomal dominant cerebellar ataxia, ARCA=autosomal recessive cerebellar ataxia, FRDA= 
Friedreich’s ataxia, spo=sporadic ataxia, MSA=multi system atrophy, HSP=hereditary spastic paraparesis. 
 
 
Figure 2. Worldwide distribution of the most common SCA subtypes  
 
SCA1 
6 % SCA2 
15 % 
SCA3 
21 % 
SCA6 
15 % SCA7 
5 % 
SCA8 
3 % 
Rare forms 
5 % 
Unknown 
30 % 
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Genetic classification 
Hereditary ataxias can be divided according to the mode of inheritance; dominant, recessive 
and X-linked (Fragile X premutations and X-linked sideroblastic anemia and ataxia, will not 
be discussed here) and further subdivided into the exact disease causing gene. The number of 
ARCA and ADCA is increasing every year and over 40 hereditary ataxias genes are already 
known. 
 
Autosomal dominant cerebellar ataxias-ADCA 
The dominant ataxias can be divided in two forms; the episodic forms and the progressive 
forms. 
The progressive forms are characterized by cerebellar ataxia resulting in unsteady gait and 
often poor coordination of hands, legs, speech and eye movements. Additional signs and 
symptoms may occur, such as cognitive impairment, tremor, polyneuropathy, epilepsy and 
myoclonus. Thirty-three different genetic loci have been mapped to different forms of ADCA.  
They are referred as spinocerebellar ataxia (SCA) in the genetic nomenclature and given 
names chronologically from SCA1 found in 1993 (59) and up to SCA35 and 36 described in 
2011 (60-63). DRPLA has never got a SCA number, but classified under the progressive 
ADCA. 
Seven forms are described for the episodic forms and chronologically called episodic ataxias 
(EA) 1-7(10).  
Spinocerebellar Ataxia –SCA and DRPLA  
SCA1-36 and DRPLA comprise a wide spectrum of diseases with different genetic 
mechanisms causing the disorders (63). Trinucleotid expansions are the mechanism behind 
SCA1-3, 6, 7, 17 and DRPLA, also called polyglutamine expansions SCAs. More recently 
expansions in non-coding regions were found to be the genetic mechanism behind SCA8, 10, 
12, 31 and 36. The third main genetic mechanism is conventional mutations, causing SCA5, 
11, 13, 14, 15, 23, 27, 28 and 35.  Figure 3 presents an overview (63;64). When the 
ITPR1gene was found, SCA15 and 16 appeared to be the same disorder which is today called 
SCA15/16 (65-67). The same is probably true for SCA19 and 22. The latter are located on the 
same chromosomal region, but the gene is not yet found (68). SCA24 proved to be a recessive 
disorder and is therefore withdrawn from the SCA list. SCA9 and SCA33 (63) is not yet 
published, but the numbers are reserved.  
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Figure 3. An overview of the different spinocerebellar ataxias (SCA) divided into different 
genetic groups 
 
Data from August 2011, *without a SCA number. SCA9 and SCA33 are reserved, SCA24 is reclassified to 
SCAR4. Bold; Coding polyglutamine expansions, italic; non-coding expansions. 
 
Polyglutamine expansion SCAs 
These disorders (SCA1,2,3,7,17 and DRPLA)  are characterized by variable degrees of 
degeneration and dysfunction of the cerebellum and the brainstem with variable age of onset, 
but as a main rule often onset in the third or fourth decades (4;6;12-15;21;69). These are 
neurodegenerative disorders leading to death by brainstem failure and can be referred to as 
ADCAI according to Harding’s classification system (Table 1). Cerebral MRI most often 
reveals severe brainstem atrophy in addition to atrophy of the cerebellum (6) (Figure 4).  
Anticipation is observed in SCA with CAG trinucleotide repeats. Anticipation refers to earlier 
onset and increasing severity of the disease from generation to generation due to higher 
number of CAG repeats. Anticipation is severe in SCA7 trough paternal transmission and 
reported with infantile aggressive forms (70;71). These disorders manifest above a threshold 
of CAG repeats, which differs in each gene. It is difficult on clinical basis alone to give an 
exact diagnose because of locus heterogeneity, i.e., mutations in many different genes cause 
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the same phenotype. There are some clinical clues which may be of help in finding the genetic 
diagnosis given in Table 5 and in Appendix 1 (6;13;20;21;63;64). Gait difficulties are the 
main clinical feature in most of these patients, but double vision, dysarthria, impaired writing, 
episodic vertigo can precede the atactic gait in some patients. SCA6 differs from the other 
polyglutamine SCA in many respects. Clinically it is characterized by later age of onset, 5-6th 
decades, is often slowly progressive, episodic symptoms can be observed initially and the 
atrophy is mainly in the cerebellum. SCA6 is therefore often referred to as ADCAIII (Table 
1). In SCA7 retinopathy in addition to the cerebellar signs is seen and therefore easy to divide 
from the other polyglutamine SCAs. SCA7 can be classified as ADCAII. 
 
Figure 4 a. SCA1 patient with cerebellar atrophy and thinning of the brainstem. b. Patient 
with SCA14 with vermian atrophy without other cerebral changes.  
 
   a.          b.    
 
 
Non-coding expansion SCAs 
Untranslated repeat expansions causes gait ataxia in SCA8, 10, 12, 31 and 36 (61;64). They 
give all a milder phenotype with a wide range of onset compared to the coding expansion 
disorders and less brain stem involvement. SCA8 was the first published repeat expansion 
SCA in an untranslated region. It is characterized by repeat instability and with no correlation 
between repeat length and penetrance and the diagnose SCA8 remains therefore controversial 
(6;72). Many of these disorders seem less frequent compared to the coding expansion SCAs 
and the relative frequencies are yet not established (6;64). In Table 5 and Appendix 1 there 
are some more details about the disorders (6;25;63;73).
Both patients from our cohort 
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Conventional mutation or rearrangements SCAs 
These disorders comprise SCA 4, 11,13,14,15,23,27,28 and 35. It seems that hereditary 
ataxias due to conventional mutations or rearrangements are less frequent than polyglutamine 
expansions, have a milder disease progression, often earlier age of onset, but with a wide 
range of disease onset and little or no brainstem involvement. These disorders typically show 
cerebellar atrophy in variable degrees on brain MRI (Figure 4). The disorders do not, as a 
main rule, influence the life expectancy. There are often lacks of phenotype-genotype 
correlations among these disorders and therefore often difficult on clinical grounds alone to 
give a certain SCA diagnose, but some symptoms and finding can differ and these are listed in 
Table 5 and Appendix 1 (6;25;63;73). 
 
Episodic ataxias 
Episodic ataxias (EA) are characterized by intermittent symptoms or episodes with cerebellar 
dysfunction (dysarthria, dizziness, ringing in the ears, unsteadiness) that can vary in duration, 
lasting from minutes to days with subtle symptoms/findings between attacks (cerebellar 
findings in EA2 and myotonia in EA1). They are also referred to as ion-channel disorders, 
because mutations in ion-channels or related genes are found (10;25;63). These disorders have 
a higher frequency of epilepsy and migraine. Attacks can be as frequent as several times a 
week, but may occur much less frequently. Precipitating causes are often attributed to; 
alcohol, caffeine, stress and physical exercise. On the other hand rest and sleep may 
contribute to reverse or to stop the attacks. The attacks may respond to antiepileptic drug, 
especially for episodic ataxia type 2. Acetazolamide should be tried when an episodic ataxia is 
suspected. EA can be difficult to diagnose, because symptoms and signs are absent or sparse 
between the attacks particularly in the beginning of the disease course.  
EA1 and 2 are the most common forms, EA3-7 only published in few families. The mutations 
found in EA2 are in the same gene (CACNA1a) as found in SCA6 and in some forms of 
hemiplegic migraine.  
 
Autosomal recessive cerebellar ataxias-ARCA  
There are no good definitions for these disorders which comprise a huge group of 
neurodegenerative disorders affecting the cerebellum and its pathways and often also the 
peripheral nervous system. Many of these ataxias are rare and reports from few families are 
published. Some of these disorders are described with loci (63). The numbers of ARCA is 
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growing every year, but still the main causes of ARCA worldwide include Friedreich’s ataxia, 
ataxia telangiectasia, AVED and ataxia with oculomotor apraxia type 1 and 2 (8). Non-coding 
expansions are the genetic mechanism behind Friedreich’s ataxia, conventional mutations in 
the other described ARCAs. Most of the autosomal recessive ataxias have an early onset and 
as a main rule before the age of 20 years (Table 5), but with many exceptions (25;63). The 
typically neuropathologically findings are degeneration of the cerebellum and/or the dorsal 
column, brainstem and spinocerebellar long tracts. The symptoms and signs are unsteady gait, 
poor balance, coordination problems, dysarthria, dysphagia, pyramidal signs, polyneuropathy 
and/or postural tremor. Some forms have in addition to these symptoms other organ 
manifestations, such as diabetes mellitus, cardiomyopathy and scoliosis seen in FRDA. The 
most common ARCA are listed in Table 5 and described briefly in Appendix 2 (8;25;63;73-
75).  
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Table 5. Genetic classification of the different ADCA and ARCA with chromosome position, 
gene (when known), age of onset and main clinical symptoms and signs. 
NAME LOCUS/GENE ONSET (YEARS) SYMPTOMS AND SIGNS IN ADDITION TO THE ATAXIA 
Dominant    
SCA1** 6p23/ATXN1 30-40 Pyramidal and extra-pyramidal signs, mild cognitive impairment. Brainstem 
atrophy. Early swallowing problems 
SCA2** 12q24/ATXN2 20-40 Pyramidal signs, optic atrophy, chorea, dystonia. Slow eye movements. Brainstem 
atrophy 
SCA3** 14q32.12/ATXN3 1-60 “Machado-Joseph disorder”, pyramidal and extra-pyramidal signs, dementia, 
ophtalmoplegia, bulging eyes. Myokymias.Brainstem atrophy. 
SCA4 16q22.1 30-50 Extra-pyramidal signs, sensory neuropathy 
SCA5 11q13/spectrin-
SPTBN2 
10-50 Pyramidal and bulbar signs  
SCA6** 19p13/CACNA1A 20-65 Sensory neuropathy, can be episodic in the beginning, same gene (see EA2) 
SCA7 3p14.2/ATXN7 1-45 Retina/macular degeneration. Pyramidal and extra pyramidal signs, brainstem 
atrophy 
SCA8 13q21/ATXN 8 18-65 Tremor, mild spasticity and sensory neuropathy  
SCA9 Reserved   
SCA10 22q13.31/ATXN10 14-44 Epilepsy and dementia 
SCA11 15q15.2/ TTBK2 20-40 Slight pyramidal signs 
SCA12 5q32/PPP2R2B 8-55 Extra-pyramidal signs, tremor, dementia 
SCA13 19q13.33/KCNC3 10-60 Pyramidal signs, mental retardation 
SCA14** 19q13.4/PRKCG 10-59 Slight extra pyramidal and pyramidal features, myoclonus, slow progression  
SCA15/16 3p26 / ITPR1 Early Hyperreflexia, tremor, slow progression.  
SCA17 6q27/TATABP 19-45 Dystonia, bradykinesia, dementia, chorea like, brainstem atrophy 
SCA18 7q22-q32 10-30 Axonal sensory neuropathy, pyramidal signs, tremor 
SCA19/22? 1p21-q21  Postural tremor, cognitive decline, myoclonus 
SCA20 11p13-q11 19-64 Palatal tremor and myoclonus, tremor, nucleus dentatus calcification seen in some 
subjects on MRI of the brain, spasmodic cough, dysphonia 
SCA21 7p21.3-p15.1 6-30 Postural tremor, extra-pyramidal signs, cognitive decline 
SCA22/19? 1p21-q21 10-46 Mild ataxia with cognitive decline 
SCA23 20p13/PDYN 43-56 Slow progression, neuropathy, dysarthria 
SCA24-
reclassified 
1p36 20-30 Pyramidal signs, myoclonus, reduced joint sense, pes cavus. Renamed to; SCAR4-
spinocerebellær ataxia recessive 4 
SCA25 2p21-p15 1-39 Areflexia , many with sensory neuropathy, gastric problems in some subjects 
SCA26 19p13.3 26-60 Mild, late onset, a Norwegian family published 
SCA27** 
13q34/FGF14 
15-20 Cognitive impairment, tremor exacerbated by physical exercise and emotional 
stress, dyskinesia, neuropathy 
SCA28 
18p11.21/AFG3L2 
12-36 Pyramidal signs, ptosis, opthtalmoparesis, early onset 
SCA29 
3p26 
Early childhood Non-progressive, some subjects with cognitive impairment, nystagmus 
SCA30 4q34.3-q35.1 ~50 Late onset, relatively pure ataxia 
SCA31 16q21-22/ BEAN 20-72 Some subjects have sensory hearing loss, nystagmus 
SCA32 7q32-q33 Variable Mental impairment, azospermia (infertile men) 
SCA33 No information   
SCA34 6p12.3-q16.1 Early onset Sparse information yet, erythrokeratodermia 
SCA35 20p13/TGM6 ~40 Dystonia, tremor in some subjects, pyramidal signs 
SCA36 20p13/NOP56 43-58 Tongue fasciculations and atrophy, muscle faciculations and atrophy,  
DRPLA 12p13/DRPLA 10-70 Choreoathetose, dementia, myoclonus, epilepsy 
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Episodic ataxia 
EA1 12p13.32/KCNA1 <10-20 Myokymia, hand, head and foot movements during attacks. Attacks lasting 
typically seconds-minutes 
EA2** 19p13.2/ CACNA1A <10 Nystagmus, tinnitus. Attacks followed by fatigue. Migraine. Attacks last often 
many minutes to hours. 
EA3 1q42 30-60 Short-lasting attacks with vertigo, tinnitus, diplopia, nystagmus, myokymia 
EA4 Probably the same as 
EA3 
20-50 Headache, tinnitus, diplopia, vomiting, nausea, myokymia 
EA5 2q23.3/CACNB4 20-60 Epilepsy, vertigo, attacks may last for hours. Nystagmus 
EA6 5p13.2/SLC1A3 <10 Vertigo, diplopia, nausea, hemiplegic  migraine, some headache headache, 
dysarthria 
EA7 19q13 <20 Vertigo, weakness, dysarthria 
Recessive    
FRDA1** 9q11-q13/frataxin 1-60 Neuropathy, multi-organ disorder. Loss of position sense. Cerebellar symptoms are 
a late sign. The ataxia seen is mostly due to dorsal columns degeneration. 
FRDA2 9p23-p11 1-20 FRDA-like. Neuropathy, multi-organ disorder 
AVED** 8q12.3/α-tocopherolTP <20 FRDA-like. Areflexia, neuropathy, weakness, tilting of the head 
A-T** 11q22.3/ATM <3 Oculomotoric apraxia, multi-organ disorder, elevated α-foetoprotein, increased 
risk for cancers and infections  
AOA1 9p13/aprataxin 1-6 Oculomotor apraxia, neuropathy, choreoathetose, hypoalbuminemia, 
hypercholesterolemia 
AOA2/ 
SCAR1** 
9q34/senataxin 10-25 Nystagmus, sensory neuropathy, oculomotor apraxia, elevated α-foetoprotein , 
chorea/dystonia and/or tremor  
SCAN1 14q31/TDP1 13-15 Axonal sensori-motoric neuropathy, hypoalbuminemia, hypercholesterolemia. 
Muscle atrophy 
ARCA1/SCAR8 6q/SYNE1 17-46 Pure, some with increased reflexes, slow progression, dysarthria. 
ARSACS 13q12/SACS 5-15 Spastic ataxia, neuropathy, retinal striation in some subjects 
ARCA2/SCAR9 1q44.2/CABC1 Childhood Pure recessive ataxia with some pyramidal signs, cognitive decline reported in 
some subjects. 
SCAE** 15q26.1/POLG1 Early childhood Neuropathy, epilepsy, classified with mitochondrial disorders* 
MSS 5q31/SIL1 Early childhood Congenital cataract, weakness, myopathy, delayed psychomotor development, 
short stature, hypogonadism 
PHARC** 20p11.21-1/ABHD12 Teenage Hearing loss, polyneuropathy, retinitis pigmentosa, pyramidal signs, cataract 
Ataxias with expansions are marked in Italic 
DRPLA=dentatorubral-pallidoluysian atrophy, EA=episodic ataxia, FRDA=Friedreich’s ataxia, AVED=ataxia with vitamin E deficiency, A-
T=ataxia telangiectasia, AOA=ataxia with oculomotor apraxia, SCAN1=spinocerebellar ataxia plus neuropathy type 1, 
SCAE=spinocerebellar ataxia with epilepsy, ARSACS=autosomal recessive spastic ataxia Charlevoix-Saguenay, MSS=Marinesco-Sjøgrens 
syndrome, PHARC= polyneuropathy, hearing loss, ataxia, retinitis pigmentosa and cataract 
For more clinical details for SCA1-32 and ARCA see appendix 1 and 2. 
*Mitochondrial disorders not included in this table, see Table 2. 
** To the author’s knowledge found in Norway 
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Pathophysiology 
Many pathophysiological mechanisms are found to cause hereditary ataxias (6;13;15;20;76-
79) including altered gene expression, synaptic transmission and intracellular signaling 
pathways. Other pathways involved are altered mitochondrial function, RNA metabolism and 
phosphorylation-dependent intracellular signaling. 
The cell mainly suffering from these alterations is the Purkinje cell in the cerebellum which 
degenerates. The inherited ataxias are often caused by mutations in seemingly unrelated genes 
causing either gain-of-function or loss-of-function of the protein. Molecular pathways that are 
essential for Purkinje cells function and survival are of particular importance. 
 
Altered gene expression 
In SCA1, 2,3,6,7 and DRPLA gain of function is one of the many mechanisms involved. In 
many of these disorders toxic accumulation of protein aggregates in the cell is found leading 
to cell death. 
Chromatin remodeling as an altered transcription of proteins is seen as one of probably many 
pathophysiological mechanism in SCA7, 8 and FRDA. In SCA1 both gain and loss of 
function of the protein are seen altering RNA splicing and transcription. In addition 
accumulation of toxic proteins and altered levels of the β-III spectrin protein is found in 
SCA1 mouse models. In SCA6, mutations in a calcium channel unit are found. Probably the 
toxic gain of function mainly explains the pathology seen in SCA6 rather than the altered 
synaptic transmission also seen in this disorder.  
 
Altered synaptic transmission and intracellular pathways 
Many of the SCAs have mutations that give rise to altered synaptic transmission and 
intracellular signaling pathways. The Purkinje cells seem particularly vulnerable to altered 
levels of calcium and glutamate. Mutations in the inositol-triphosphate receptor seen in 
SCA15 seem to alter the output of calcium from the endoplasmatic reticulum and decrease the 
levels of calcium inside the cell. β-III spectrin protein stabilizes a glutamate transporter 
protein on the cell surface and mutations in the β-III spectrin gene seen in SCA5 decrease 
reuptake of glutamate from the synapsis and strengthens the glutaminergic signaling. In SCA6 
accumulation of mutant calcium channels will influence the calcium transport in the cell 
membrane. Also mutations in other ion-channels proteins seem important for synaptic 
24 
 
transmission, for instance the mutations in potassium and sodium channel genes seen in 
SCA13 and SCA27.  
The mechanisms mentioned in this chapter are not well understood and whether these 
pathways function independently or are interconnected remains to be further explored (80).  
Genetic testing and how to diagnose hereditary ataxias 
Diagnoses are based on the patients’ medical history, family history and a complete 
neurological evaluation including a MRI scan of the brain (Figure 4), blood samples, 
neurophysiological investigations and if necessary lumbar puncture (5;8-20;25;45;81). It is 
much easier to give a hereditary ataxia diagnosis when a family history is established. In 
sporadic cases clinicians must carefully exclude all known secondary causes to a progressive 
ataxia. As a rule more than one family member should be examined because of the inter- 
and intrafamiliar heterogeneity in these disorders. 
Molecular tests are now available for many types of hereditary ataxias (82). International 
guidelines are to test for SCA1, 2,3,6,7 and 8 in dominant cases because these genotypes 
represent over 50% of the affected families. It is also recommended to test for FRDA in 
recessive/isolated cases (6;8;9). It is further recommended to test for the different recessive 
forms when having positive biomarkers (see discussion) or if the phenotype is compatible 
with the genotype according to the neurological examination and the supplementary 
investigations (blood samples, MRI of the brain and medulla and neurography). As a main 
rule ARCA or another recessive disorder with an atypical phenotype are more likely than 
idiopathic sporadic ataxia when onset occurs before the age of 20 years (8;81). 
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Aims of the study 
The primary aims of this study were: 
1. To find the prevalence of HA  in a defined population 
2. To find the occurrence of known described phenotypes and genotypes in this 
population 
3. Explore the Norwegian ataxia population and investigate carefully selected 
phenotypes and determine the genotypes 
4. The ultimate goal was to identify a new phenotype in the Norwegian ataxia 
population and find a new gene/locus explaining this phenotype. 
 
The secondary aims of this study were: 
1. Propose rational diagnostic and follow-up strategies, based on the prevalence and 
occurrences of each form. 
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Material and methods 
Patients and control material 
To identify all patients with hereditary ataxia we used several search strategies: 
 
1. We established a tight collaboration with colleagues in hospitals and departments all 
over southeast Norway (genetic, pediatric and neurological departments)  
2. We searched in hospital journal archives back to 1992 
3. We had a tight collaboration with the patients’ association (NASPA)  
4. A detailed family history was taken in every index patient. We investigated as many 
affected members as possible in each family 
 
In the prevalence study the STROBE-statement checklist (Supplement 1) was used in order to 
get as reliable data as possible and to report our results in an informative way (83).  
 
Inclusion and examination of the patients 
All adult patients included were examined by Jeanette Koht and /or Chantal Tallaksen and 
Anne Kjersti Erichsen according to two standard clinical charts established by the SPATAX 
network (Supplement 2 and 3) (84). All clinical data were systematically registered in a 
database. Symptoms and signs were described in details after clinical investigations for each 
patient and all supplementary investigations were stored in the same database and in binders. 
Supplementary investigations including cerebral MRI were performed in as many as possible 
in each family. The hereditary ataxia diagnosis was in some families easy to make due to 
family history and typical symptoms. In other patients painstaking supplementary work was 
done. All index patients were investigated following updated diagnostic criteria in order to 
exclude wrong diagnosis and include correct patients (5;6;8;9;11-15;17-21;23;51;57). Patients 
were diagnosed with hereditary ataxia if they fulfilled the inclusion and exclusion criteria in 
Table 6. 
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Registration of the patients and controls 
Each index subject was registered in the research database using the Excel 2003 software. All 
investigators filled in clinical data continuously into this database. The database included the 
standardized clinical sheets of the patient, geographical origin, consanguinity, the pedigree 
and additional clinical information such as results from supplementary investigations (MRI, 
nerve conduction examinations and blood samples). All index subjects were categorized into 
one of the four groups; autosomal recessive, dominant, X-linked trace or sporadic forms. The 
latter subjects were not included in this work. Whenever it was necessary to do statistical 
calculations the data was transferred to the SPSS 16.0 software.  
The prevalence date was set to February 1, 2008 and the database was at that time frozen for 
calculations for the prevalence study, but the inclusion of patients was at the same time 
ongoing the whole study period and therefore more ADCA families were included in Paper 3. 
Table 6.  Diagnostic criteria for hereditary ataxia in our study 
Inclusion criteria (1,2,3 or 1, 2 or 1, 3): Exclusion criteria: 
1. Progressive cerebellar ataxia 
2. Other family members with HA 
3. Verified molecular diagnose 
 
1. Secondary ataxias 
2. Sporadic ataxias  
a) no family members affected  
b) no verified molecular diagnose  
 
Collection of DNA  
A blood sample was collected from each index subject and all available and informative 
subjects in the families included for further linkage studies. DNA was extracted from 
leucocytes from a blood sample using standard procedure at the Department of Medical 
Genetics, Ullevål.  
 
Selection of families 
Families were included for further linkage studies if the theoretically LOD score was >3. All 
index subjects with dominant trace were enrolled in the study for diagnosing newly known 
genotypes (Paper 3). 
Molecular methods 
To give patients exact genetic diagnoses and find new genes/seldom genotypes different 
strategies were used; 
1) Sequencing already known genes 
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2) Sequencing already known, but seldom genes using a combination of candidate gene 
approach and linkage study with microsatellites flanking the region(s) containing the 
gene/genes 
3) Whole genome linkage study in order to find new genes/locus 
 
 
After Paper 1 we had included 171 subjects/87 families with HA, of these 111 subjects/48 
families with ADCA.  Many of these families were small, consisting of only 1-2 affected 
subjects alive.  
Families with more than 6 affected available for investigations and blood samples were 
considered as candidates for linkage analyses. Power analyses with the simulation program 
fastS-LINK of the EASY linkage software program were used (85). After these analyses we 
choose three ADCA families with different phenotypes for further linkage studies.  
Linkage analysis is based on identifying chromosomal regions co-segregating with the disease 
in the family and the identified region is expected to harbor the disease causing mutation (86). 
The further apart two loci are on the same chromosome the more likely it is that 
recombination has happened. Chromosomal regions are broken up during the meiosis and 
recombination information is utilized in linkage studies. A linkage analysis of the whole 
genome can identify loci that show evidence of containing the disease causing gene. The 
principle of linkage study with recombination/crossover events is shown in Figure 5 for one 
chromosome in a small autosomal dominant family, as seen in the figure a part of the 
chromosome (often referred to as the shared haplotype) are inherited together as a block.  
Genetic markers are used to genotype individuals (making a chromosome map) and utilized 
when performing linkage studies. Microsatellites and SNP (single nucleotide polymorphism) 
are today commonly used to genotype individuals and were used in Paper 3 and 4. A 
microsatellite marker (simple tandem repeat polymorphism) is made of repeats of two, three 
or four base pairs and varies in length between individuals. On one chromosome, there might 
be six repeats (CACACACACACA), while on the other chromosome there might be ten 
(CA10). Microsatellite markers are easy to genotype, have multiple of alleles and they occur 
almost everywhere across the chromosomes. The principle of genotyping microsatellites is 
based on analyzing the size of the fragments amplified with primers flanking the 
microsatellites. The size of the amplification product varies depending on the number of 
repetitions in each specific allele. The analysis in this work was carried out on a sequencer 
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ABI PRISM 3730 Genetic Analyzer (Applied Biosystem) which measured the migration of 
the DNA fragments in a capillary loaded polymer and then analyzed by the software Gene-
Mapper 4.0 (Applied Biosystem). The results are presented as peaks, with the base pairs (bp) 
numbers at the x-axis and the fluorescence intensity in the y-axis (Figure 6). 
 
Figure 5. An example of cross-over events (recombinations) in an autosomal dominant family 
  
  
 
 
Figure 6. Example from the genotyping with microsatellites. D19s921was one of many 
genotyped markers used in Paper 3.  
 
 
 
 
 
Subject 21 is heterozygous for the alleles with the sizes 228 bp and 236bp, translated to 3/2 which 
makes it easier read. Subject 22 is heterozygous for the alleles with the sizes 230 bp and 236 bp, 
translated to 5/2.  
Square=male, circle=female. Filled=affected, Clear=unaffected 
individuals. In the pedigree the affected siblings share the violet 
haplotype. The green haplotype has to be healthy due to the 
healthy brother 2-4. Sibling 2-3 has a part of the violet haplotype 
and a recombination has occurred. This means that the mutated 
gene is more likely located between the two red lines marked. 
 
30 
 
The SNP markers have their variations at a single base on the chromosome, i.e. there can be 
only three different combinations, for instant; AA, AT, TT. Enough SNP’s have been 
identified to allow a very dense coverage of the entire genome and SNP’s genotyping was 
therefore preferred in the whole genome genotyping in our families.  
LOD score is used to prove evidence for linkage. LOD score means the “logarithm of the 
odds” and is a statistical estimate of the likelihood of a linkage between two loci. The 
evidence of linkage in dominant disorders is normally set to LOD score >3 as we did in our 
families. A LOD score of 3 means that the odds are a thousand to one in favor of genetic 
linkage. If however the region is broken up during meiosis in many of the affected it less 
likely that the disease causing gene is in this region. Gene linkage is excluded if the LOD 
score is less than -2. 
Before selecting a family we performed a thorough examination of all participating members 
to find as many affected as possible in the families, in order to increase the chances to find the 
linked region and the gene.  
 
Paper 1  
The mutation analyses for SCA1, 2, 3, 6 and FRDA for the prevalence study were done as a 
standard diagnostic test at OUS, Ullevål and Haukeland Hospital, Medical Genetic 
department. The SCA8 analysis performed in selected ADCA families was done by Jørgen E. 
Nielsen, Department of Medical Genetics, Panum Institute, København as part of a 
collaborative work.  
Paper 2  
The mutation analysis was done at the Department of Human Genetics, Nijmegen Medical 
Centre in The Netherlands as a standard diagnostic test.  
Paper 3  
Genetic linkage analysis with candidate gene approach was a good method to use before 
starting the time consuming sequencing step. Linkage to the chromosome 19q13.4 region was 
therefore tested in dominant families who had tested negative for mutations in the SCA1, 
2,3,6,7 and 8 genes and who were informative for linkage studies. The families were 
investigated with microsatellites flanking the SCA13 and 14 genes and haplotypes were then 
manually drawn. Selected exons in the SCA14 gene were sequenced in two families and all 
index cases in our ADCA cohort at that time.  
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Microsatellites primers were designed with Primer3 software program (87). Exons 1, 2, 3, 4, 5 
10 and 18 were amplified by PCR in an Abi-Veriti apparatus using the primers and conditions 
mentioned in Table 7. The standard set-up for the PCR reaction used in these studies is shown 
in Figure 7. PCR amplified fragments were purified with exonuclease 1 and phosphatase and 
sequenced in an ABI automated sequencer in the forward and reverse direction with the PCR 
primers and with a BigDye kit (Applied Biosystem) (88). Segregation of the mutation was 
verified by direct sequencing in all family members were DNA were available. The mutation 
was supported by LOD scores. 
In addition 576 healthy control chromosomes from Norway, France and North Africa were 
screened for the same mutation. The identified missense mutation was also checked in a 
bioinformatic program (Polyphen). 
Paper 4 
Two families with a theoretically measured LOD score>3 was chosen for SNP microarray 
genotyping followed by linkage analyses. One of these families is described in Paper 4, the 
other family is not yet published. In this paper ten family members were genotyped with 6090 
SNP markers using the Illumina Gene Chip Human Mapping array at the platform situated at 
the Hospital Salpêtrière. The markers in this array are spanning all chromosomes with an 
approximately average genetically distance at 0.58 cM and an average physical distance at 
441 kb. Standard protocol supplied by the manufacturer was followed. The procedure was 
done by Wassila Carpentier at P3S plateforme, Pitié-Salpêtrière Hôpital, Paris.  
PedCheck program was used to detect the pedigree file for Mendelian inconsistencies in the 
pedigree data (89). Linkage analyses were performed using the Merlin 1.0 Software package 
(90) and the Allegro package (91). For the disease allele the penetrance was set at 0.8 and 
with a gene frequency at 0.00005 in the general population. 
To confirm linkage to the regions with positive LOD scores additional heterozygous 
microsatellite markers were used and primers were designed with Primer3 software program 
(87) covering the possible linked regions, Table 8. Haplotypes were drawn manually for all 
loci. 
The INPP5gene, (coding regions, UTRs and splice site junctions) was sequenced by 
Genoscreen in Lille in France in an automatic ABI3730 sequencer (Applied Biosystems). 
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Table 7. Primer pairs and annealing temperatures used for amplification and direct 
sequencing selected exons in the PRKCG gene (Paper 3). 
Exon 
number 
Annealing temperature Primer forward Primer reverse 
EXON 1 72-62°C CGCCCTCTCGGTCGTCCTG AGCCCCCTCCTTCTTCCTTC 
EXON 2 65-55°C GGGTCTGAAGGAGGAAGAAA CAAATATCTGTCCCCACCTG 
EXON 3 58°C CGCTCTCTCTTTCCAATTTT GAGGAGGAGAACCAGGTGT 
EXON 4 62°C GAGAGCAAGGCAGGAGGAAA CCCCAAGCCAAGACTCCA 
EXON 5 60°C GCATGAAATGCTCCTGTGAC GGCGTGACCATAGAAAGAGG 
EXON 10 60°C  GTGGCCATTTTCCTCTGTCT ACCTCTCCTCTCCAGGAACC 
EXON 18 58°C GTGCAGACACCATGAAGCAT GGGAGGCACAGAACTACCAA 
 
Table 8. Primer pairs, annealing temperatures and positions for the microsatellites used to 
confirm linkage to chromosome 10 in Paper 4 
Marker Heterozygousity Position cM Temp.°C Primer forward Primer reverse 
D10S1676 0.67 129896120 159.78 55 CCACCACTCAGAGGTAAGG AATTGTATGATCCCAACTTTG 
D10S1248 0.76 130982451 166.09 55 TCTCTTTTTCCCTTGTCTTG TCTCTTTTTCCCTTGTCTTG 
VNTR14GT Unknown 132200000 ? 55 GCTTGTTGTGAGGCAGATGA TCTTGGGTGTCCATGGTAGG 
D10S169 0.71 132411477 169.48 55 AAGGTATAACGAGGCAGTCC GACAGGGATCACTTTTCAGA 
D10S1770 0.88 132575634 170.04 55 CACTATCCCTTCATCCATCC ATCCATCAGCTCTCCAGTCG 
D101675 0,71 133428283 172.22 55 GAAGGAGCTACCACTGTGAG GTGCTGTTTGTGCATGTTAT 
D10S590 0.59 133497512 172.22 55 GTGGTCTCTGCCACACCTA GCACAGTCTGCTGCATCTC 
D10S212 0.66 134299489 174.19 55 GAAGTAAAGCAAGTTCTATCCACG TCTGTGTACGTTGAAAATCCC 
D10S1700 0.72 135026673 175.02 55 TGTGTTGGAGTAGGACGTGA ACAGATGCGTGTACAGATGC 
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Figure 7. The principle for Polymerase chain reaction (PCR) for the DNA amplification  
 
Statistical methods 
In Paper 1 the Fleiss’s method was used to calculate age, sex and county-specific rates (92) 
and the Poisson model (93) was used to estimate the prevalence in the different counties. 
Before starting the study we performed a power analysis in order to capture the real 
prevalence of these disorders.  
In addition descriptive statistics were performed in all papers.  
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Results 
For the prevalence study (Paper 1) 171 patients with hereditary ataxia were included, 365 
patients all together (including HSP), the prevalence day was set at 1.February 2008. All later 
papers were based on this study and the families found in the prevalence study were then 
further explored for the genetic studies (Paper 2, 3 and 4).   
Paper 1 
All collected patients are shown in Figure 8 with prevalence estimations for ARCA and 
ADCA and distribution of patients according to ages. The prevalence increased with age, with 
the highest prevalence in the age group over 60 years. Clinical data is given in Table 9.  
Thirteen small dominant families (21 subjects) had a pure phenotype with late disease onset 
(>40 years). Twenty-four of the 111 subjects were of non-Norwegian origin. Very few 
families with the well-known SCA1, 2, 3, 6 and 7 were found. Only 8% of the families in the 
ADCA group were given a genetic diagnosis and 46% among recessive families (Figure 9). 
SCA3 was the only dominant genetic disorder among dominant Norwegian families. A-T was 
the most common recessive ataxia form and FRDA was found in surprisingly few recessive 
subjects. Both AOA2 (74) and AVED (Paper 2) were diagnosed among Norwegian ARCA 
patients. 
 
Table 9. Clinical data at prevalence day, 1.February 2008. 
  ADCA  ARCA  
Mean age at disease onset (range), years 32 (1-72) 9 (1-55) 
Mean age at prevalence day (range), years 57 (13-94) 32 (4-71) 
Percentages of the patients using wheelchair 6.3 40.7 
ADCA-autosomal dominant cerebellar ataxia, ARCA-autosomal recessive cerebellar ataxia 
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Figure 8. Flowchart of all included and excluded ataxia subjects and distribution of ADCA 
and ARCA subjects by ages. 
 
  
 
2. Computer search 
N=105 
186 subjects with progressive ataxia 
 
3. Patients association 
N=4 
 
1. Colleagues  
N=77 
 
86 subjects excluded 
82 sporadic forms 
4 died 
171 subjects with HA included 
ADCA prevalence 4.27/100 000 (111 subjects/48 families) 
ARCA prevalence 2.27/100 000 (60 subjects/39 families) 
 
  ADCA subjects ARCA subjects 
0-19 years 3 25 
20-39 years 15 11 
40-59 years 36 16 
> 60 years 57 8 
Total  111 60 
Secondary ataxia subjects excluded 
 
Population in southeast Norway 
2.63 million inhabitants in 2008 
 
71 family members included 
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Figure 9. ARCA and ADCA occurrences in our HA cohort in 2008. Percentage of the families 
with the different genetic diagnosis 
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gene, but with a FRDA-like phenotype. 
ADCA-autosomal dominant cerebellar 
ataxia, ARCA-autosomal recessive 
cerebellar ataxia  
37 
 
Paper 2 
In Paper 2 we reported the first genetically confirmed subject in Norway due to mutations in 
the α-tocopherol transport protein gene resulting in vitamin E deficiency. Through the 
systematic population-based study of hereditary ataxia in southeast Norway one patient with 
ataxia with vitamin E deficiency (AVED) was identified among the 39 recessive families and 
82 sporadic subjects included.  
The subject was a 45 years old woman with progressive ataxia from preschool age. She was 
given a diagnosis of FRDA in the early eighties after clinical examination before genetic tests 
were available. At the age of 45 re-evaluation and re-examination were performed as part of 
the project and vitamin E analysis and genetic analysis were done. Vitamin E in serum was 
undetectable and genetic analysis detected a compound heterozygous mutation, A120T and 
R134X, in the α-tocopherol transport protein gene on chromosome 8q13. Clinically the 
patient had a FRDA phenotype with truncal and extremities ataxia, pes cavus, inverted plantar 
response, loss of proprioceptive and vibration sense and a severe sensory neuropathy. In 
addition she had titubation of the head typically seen in AVED. SARA score was 30 out of 40 
points. 
Optimal treatment with vitamin E supplementation was started.  
Paper 3 
In this paper we reported a new mutation in the PRKCG gene and the first two Scandinavian 
families with SCA14. This new mutation causes a mild, slowly progressive ataxia with 
pyramidal signs in the affected family members. 
Genetic studies demonstrated linkage to the markers covering the SCA14 gene with a 
maximal bi-point LOD score of 3.21 at theta=0 for marker D19S921 in family 1 and not to the 
SCA13 gene in one family (Figure 10). Haplotype analysis identified shared alleles at 3 
microsatellite markers for these two families in the chromosomal region surrounding the 
SCA14 gene, suggesting a shared ancestral chromosome. These families were from the same 
small geographically region in Norway.  Direct sequencing revealed a novel C to A missense 
mutation at position 417 in exon 5 in the PRKCG gene (Figure 11). The wild type amino-acid 
was in a highly conserved region in the gene and was perfectly conserved in all mammals and 
in other protein kinases and was predicted with in silico analysis to be damaging to the protein 
stability (Polyphen). The mutation co-segregated with the affected family members. The 
mutation was absent in 576 control chromosomes. One healthy family member (53 years) 
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carried the mutation, indicating incomplete penetrance at this age. Mutations in the PRKCG 
gene explain only 3.5% of the families in our ADCA cohort.  
 
Figure 10. SCA14 family linked to the SCA14 gene. The shared haplotype is marked with 
orange colour. 
 
 
 
 
Figure 11. Sequence chromatograms for portions of the PRKCG exon 5 (forward and 
reverse), showing the heterozygous mutation in one affected family member, changing a C to 
an A 
 
 
 
Paper 4 
In Paper 4 we reported a very late onset autosomal dominant ataxia linked to a new ataxia 
locus on chromosome 10q. Twenty-four family members were included. Mean age of onset in 
the seven affected subjects was 62 years (range 60-68). All affected had mild to severe gait 
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unsteadiness and limb incoordination that progressed slowly over years with periodic 
dizziness. All had saccadic pursuit observed at eye examination. The whole genome scan 
identified one chromosome region with a multipoint LOD score > 2. There were no linkages 
to already known autosomal dominant ataxia loci. The most suggestive evidence of linkage 
was obtained to markers on chromosome 10 with a maximal multipoint LOD score (Merlin) 
of 2.67 between SNP markers rs570967 and rs880340 at position 131311320-134903113bp. 
Genotyping additional microsatellite markers for all family members available verified 
linkage and generated a maximal two-point LOD score of 3.1 to this region.  
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General Discussion 
In our work we 1) report the prevalence of HA and occurrences of known genotypes 2) 
describe new genotypes in Norway and 3) present a new ADCA linked to a new locus. 
 
Epidemiology 
Håvard Skre did the first epidemiological study on hereditary ataxias in the seventies. With 
new genetic knowledge and improved epidemiologic methods we wished to contribute to new 
and reliable data on these disorders. Southeast Norway was well suited to do a cross-sectional 
population-based study because; 1) the population size was large enough 2) the population 
was stable and had a long average life expectancy 3) in the region we had good cooperation 
with the clinicians and 4) few private clinics and few genetic laboratories served genetic 
diseases. These factors made the sampling manageable and reliable. 
In accordance to the power analysis performed in our study, a population size of at least 1 394 
805 was required to estimate a precise prevalence. Many previous studies (Table 4) were 
conducted on small populations. Estimating the prevalence in a small population can bias the 
results. The prevalence estimation in the different counties in our study illustrates this well, 
because the prevalence ranged from 3.7 to 16.2/100 000.  
One limitation of the prevalence study was the possibility to miss hereditary forms hiding 
among the sporadic forms which we excluded. Patients with ARCA are therefore likely 
missed if no biomarkers or diagnostic tests were available and if only one subject in a family 
was affected. Also mild phenotypes were possible to miss, because patients may not be aware 
of the family disorder or they may not be followed up by a neurologist. In order to try to find 
all subjects with hereditary ataxia in southeast Norway we searched back to 1992 in the 
journals archives and had a tight collaboration with clinicians in our region and investigated 
as many family members as possible in each family. We were very strict with the inclusion 
criteria and if there was doubt about the patient’s diagnosis he/she was not included. There are 
many different disorders giving ataxia (Table 2). Sometimes it was difficult to differentiate 
ataxia from other neurodegenerative diseases, especially among children, and they were 
therefore not included. By choosing strict inclusion criteria and employing molecular testing 
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and biomarkers, we believed that we have avoided the inclusion of subjects with other 
neurodegenerative diseases in our study.  
Our prevalence estimation at 6.5/100 000 is therefore likely an underestimation rather than an 
overestimation of the true prevalence in the region.  
 
There are studies with higher prevalence estimation compared to our study. This is mainly due 
to different inclusion criteria. The study conducted in Japan (39) estimated a prevalence as 
high as 17.8/1000, because both HSP and sporadic subjects were included. If we include 
sporadic subjects (82 subjects) in our estimated prevalence study, our prevalence rises to 
9.6/100 000 if we also add HSP and sporadic spastic paraparesis the prevalence estimation 
rises to 17/100 000 and this is almost the same as the highest prevalence reported for these 
disorders. These examples also show that it is difficult to compare the different studies done 
in different areas and countries. 
In Paper 1 we showed a surprisingly high prevalence of ADCA, a high proportion of mild 
disease, a high prevalence of A-T and a high proportion of patients with undefined genetic 
diagnosis. Compared to other European countries where over 50% of the dominant ataxias are 
diagnosed after testing for SCA1,2,3,6 and 7 (6) and ~1/3 of the recessive ataxias is diagnosed 
with FRDA (81) we had a population with a high percentage of genetically undiagnosed 
subjects and a different occurrence of SCA1, 2, 3, 6 and 7 compared to other European 
countries. If we include the families explored in Paper 3 we still did not have exact genetic 
diagnosis to more than ~10% of our ADCA families (Figures 2 and 9).  
As expected the prevalence increased with age and was highest among those over 60 years of 
age and in subjects with ADCA.  Many small families with late onset and pure forms were 
without a genetic diagnose, this phenotype was explored in Paper 4. We reported also a lower 
prevalence of ARCA in older age groups, as expected because of the shorter life expectancy, 
mostly due to the high proportion of A-T among our ARCA families (8;94). 
Genotypes and phenotypes in the Norwegian cohort 
The database with spinocerebellar degenerative disorders consists in June 2011 of 564 
patients (346 families) of which 287 patients have sporadic and hereditary ataxia, 40 families 
with ARCA and 60 families with ADCA. 
Locus heterogeneity among the hereditary ataxias is a huge challenge when diagnosing 
patients. It was therefore difficult after the clinical examination to say which genotype the 
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family had. We started therefore to screen the population for the well-known genotypes. 
Linkage analyses were performed in selected families, with markers flanking known genes of 
interest or the whole genome in order to find the genotype or to find new genes. 
 
Dominant families 
Figure 12 shows all genotypes and phenotypes we have found in the Norwegian ADCA 
cohort until June 2011. 
Phenotypes 
Mild pure forms  
We have 18 families with a mild phenotype in the cohort and the new locus on chromosome 
10 (Paper 4) can explain one of these families. Seventeen of these families were 
uninformative for linkage studies, without mutations in the well-known genes and therefore 
leaving them without and exact genetic diagnosis. These families are not tested for mutations 
in all known SCA genes and it could have been of interest to test them for SCA11, 15, 28 and 
31 which all are described with relatively pure phenotypes. There are occurrence studies 
published on 11, 15 and 28 (67;95;96), but these forms does not explain more than a few 
percentages of the families in these cohorts. SCA30 (gene not found) and 31 are described as 
pure forms and published in very few families as is with many of the SCA due to 
conventional mutations (6). Due to the high expenses and the time required to sequence these 
genes it was not possible to perform molecular analyses for the SCA11, 15, 28 and 31genes in 
the scope of this work. In addition it is not considered as part of a routine testing (9). 
Also SCA26 is described with a pure phenotype and of particularly interest, because the 
family linked to this locus was originally from Norway (97). The gene is not yet found. DNA 
from selected families from this study has been sent to the group in USA, but no matches 
have yet been found. 
17 families (30% of the families in the cohort), not informative for linkage analyses seem to 
have a very similar phenotype as the family explored in Paper 4. It will therefore be of interest 
to find the gene in the linked family and further explore if we have a founder mutation in 
Norway giving this new phenotype.  
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Episodic forms 
Ten families reported episodic symptoms and were classified into this group. Two families 
had an EA2 phenotype, but tested negative for mutations in the CACNA1A gene. There are 
today many genes causing episodic ataxia and also SCA6, which is allelic to EA2, can give 
rise to episodic symptoms in the beginning of the disease. Vertigo previous to the 
development of the ataxia is often seen (98). We have not found any families with expansions 
in the SCA6 gene in our ADCA cohort. Many of these families have benefit from medication 
(Diamox). In our cohort many family members had symptoms in many years before they were 
diagnosed. We believe the number of episodic ataxia is underestimated in our study due to the 
diffuse symptoms, especially in the beginning of the disease. 
Ataxia with tremor 
Six families with autosomal dominant inheritance had cerebellar symptoms and a disabling 
intension and action tremor. One family with early onset and tremor/ataxia with pyramidal 
signs was included for further linkage studies. This is a new phenotype not linked to any 
known ADCA genes, but linked to a new locus on chromosome 3 (unpublished data). Tremor 
is reported also as an additional feature in families with SCA12, but most of the families 
reported are from Asia (99) and SCA12 seems to be a rare cause of hereditary ataxia. The 
families uninformative for linkage are not tested for mutations in this gene and we may have 
some SCA12, even though this seems to be a rare cause.  
Fragile X tremor/ataxia syndrome with an expanded trinucleotide repeat in the FMR1 gene 
(55-200 CCG expansions) can give rise to tremor and ataxia symptoms, but this disorder is X-
linked, not autosomal dominant as seen in our families, with a high degree of anticipation 
(giving rise to Fragile X syndrome), men are more often affected than woman, typical MRI 
changes can be seen as also Parkinson-like features and peripheral polyneuropathy (100).  
None of the families had this phenotype and this genotype may not explain the tremor/ ataxia 
symptoms among these families. We performed genetic testing in most families, but they 
tested all negative for mutations in the FMR1 gene. We have seen patients with Fragile X pre-
mutations during our work, but they appear to be classified among tremor patients rather than 
ataxia in Norway. No Fragile X pre-mutations were found during our prevalence study. We 
might have found a few more families using tremor diagnoses when searching in journal 
archives in hospitals. 
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Other ataxia phenotypes 
There are families with miscellaneous phenotypes, but all families were uninformative for 
linkage studies. This group was therefore not further explored in this thesis, interestingly the 
family with SCA4 (101), is originally from Scandinavia. The phenotype seems similar to 
some of the families in this cohort.  
 
Genotypes 
In monogenic diseases one mutation in a single gene alone is sufficient to cause the disease 
and the main goal will be to find as many as possible of the genes explaining these disorders. 
Linkage analysis still has a role in finding new genes, even though faster, parallel methods for 
sequencing are taking over for SNP genotyping (62). 
The linkage analysis showed evidence for linkage to markers on chromosome 10 in Paper 4.  
We found genetically confirmed SCA families in the Norwegian ADCA cohort (Figure 9), 
even though the number was small, two families with SCA14 with the same mutation, both 
families from the same region in Norway with a probably common ancestor were reported in 
Paper 3. Also two SCA3 families from Norway were investigated, but one of these has its 
ancestor from Portugal. The other SCA3 family did not know about any ancestors from 
outside Norway. The other SCA families were all from outside Norway. In Paper 3 only 
selected exons were sequenced and therefore still some families in our cohort may have 
undiagnosed SCA14. According to earlier papers on SCA14 (102;103) we decided not to 
sequence all exons in this gene. It is time-consuming to sequence exon by exon and also 
expensive and other tasks were therefore prioritized for the time I was working in the 
laboratory. The occurrence of SCA14 in our cohort was very close to what have been 
published earlier. We therefore believe the missed subjects are few.  A drawback in our work 
is of course that we did not sequence all genes causing hereditary ataxia. The growing number 
of SCA makes it even more difficult to know where to start. We have through our work 
searched among the most frequent SCAs (SCA1,2,3,6,7 and 8) and SCA14, but still after this 
work ~ 90% of the ADCA families are without an exact diagnosis.  
We did a huge effort to find the gene in Paper 4, but even though we sequenced a very good 
candidate gene in this paper and performed RNA analysis (not published) on the INPP5A 
gene, 29 more genes in these regions are not explored.  The naturally next step is to perform 
faster parallel sequencing methods and hopefully find the disease causing mutation in this 
family. 
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Recessive families 
Figure 13 shows all genotypes and phenotypes we have found in the Norwegian ARCA 
cohort until June 2011. 
Phenotypes 
Among the families in the recessive group 54% of the families are left without an exact 
diagnose. Spastic ataxia seems to be a homozygous group among the Norwegian families. Ten 
families had spastic ataxia with onset before 25 years. We have during our work tested 
selected families for ARSACS, but all families were negative for mutations in this huge gene 
(unpublished data, genetic work done by S.Vermeer in Nijmegen Medical Centre, the 
Netherlands, personal communication). No other genes are reported with this genotype to our 
knowledge and these families can therefore represent a new phenotype. Two of the 41 
Norwegian recessive families reported consanguinity, among these, one small family with 
spastic ataxia (ongoing project). Homozygous mapping is an excellent way to find new 
recessive genes or to find the exact diagnosis (104), the method is often used on 
consanguinity families or isolated populations. 
Genotypes 
Among the recessive ataxias we gave 46% of the families a genetic diagnoses (Paper 1), with 
A-T as the most prevalent diagnose due to the known Rendalen founder mutation. All 
sporadic and recessive subjects were screened for vitamin E deficiency (Paper 2) and only one 
AVED was only one AVED was found. Early screening for vitamin E deficiency in all ataxia 
subjects is strongly recommended even though it is a rare cause of neurodegenerative ataxia 
also in Norway. Two families with heterozygous mutations in the Frataxin gene were found, 
with a FRDA-like phenotype. We had very few FRDA patients in our Norwegian population 
and we hypothesized that the carrier frequency is low due to the prevalence estimation. It is 
therefore unlikely that the families with a FRDA-like phenotype and expansions in one allele 
have another ARCA in addition to this finding. These families are now further investigated by 
our group. Two families from our cohort were diagnosed with AOA2 (SCAR1) and included 
in a paper with 90 patients from a European cohort and part of the SPATAX network 
cooperation (74). 
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Figure 12. Numbers of families with the different genotypes and phenotypes per June 2011 in 
the Norwegian ADCA cohort 
 
 
 
Figure 13. Numbers of families with the different genotypes and phenotypes per June 2011 in 
the Norwegian ARCA cohort 
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Why find exact genetic diagnoses and new genes? 
Since few ADCA and ARCA, except AVED, FRDA and EA (10;11;57;105;106), have 
therapeutic options which prevent the degeneration (in greater or lesser extent) or decrease the 
episodic attacks it is always a cost-benefit question when to perform painstaking diagnostic 
work and expensive molecular analyses. There are a growing numbers of ADCA and ARCA, 
and the phenotype-genotype correlation is not always present and establishment of clinical 
criteria for genetic subtypes seems difficult (6;9). In addition testing for many HA is on 
research basis only. Many of these disorders are rare, SCA5, 11,15,23,27,28,31,35 and 36 are 
reported in few families. Screening projects have been performed in SCA11, 14, 15 and 28, 
but explained only a few percentages of the families in these ADCA populations. Except for 
the most common forms (SCA, 1, 2,3,6,7 and FRDA), the time consumed, the occurrences 
and the expenses can therefore be arguments against genetic testing for these disorders.  
On the other hand through our work we have seen the importance getting an exact diagnosis. 
For many patients it is important to know whether a disease can be prevented or treated. Even 
though few medication options exist for hereditary ataxias the test results might help a person 
to realize that they have done what is possible to treat the disease. To get a genetic diagnosis 
is important in making life decisions, such as career choice and family planning. Patients can 
get more reliable information about the disorder and prognosis and they get more exact 
answers to their problems. Family members with variable expressivity can be tested if they 
want, misdiagnoses can be corrected, genetic counselling can be performed and finally these 
subjects can probably in the future be included into medication trials.  
Research on monogenic diseases has contributed greatly to our understanding of pathogenic 
mutations, gene regulation and genetic mechanisms. Until today more than 2000 monogenetic 
disorders are found, but still more than over 1500 monogenetic disorders are only described 
with phenotypes in the OMIM (Online Mendelian disorders in Man) database (63). This 
means that more monogenetic disorders need to be explored. These future genotypes can give 
us valuable insight into the human biology.  
The impact of finding a new gene is therefore great and this was therefore also the ultimate 
aim of this thesis. We faced many difficulties in Paper 4 as for instant; difficulties obtaining 
sufficient numbers of DNA samples, difficulties in finding other families with power enough 
for linkage analyses and lack of funding because these disorders are rare.  
However, studies of monogenic diseases have contributed a great deal to the knowledge of 
complex diseases, such as Parkinson and Alzheimer. There are therefore good arguments for 
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why Mendelian disorders deserve more attention (107) and why we still search for new genes 
among the hereditary ataxia families. 
Clinical recommendations based on our work 
During our work we have tried to give patients diagnoses using different methods such as 
linkage studies, screening projects and routine diagnostic tests. Our work revealed difficulties 
and challenges in diagnosing hereditary ataxias and based on our experiences we suggest an 
approach to these patients (Figure 14).  
An accurate family history can be of valuable help. Sometimes it is important to take the 
family history from different family members to find the phenotype of importance. To 
exclude sporadic ataxia supplementary examination can be of great help (Table 2). Brain MRI 
can be used to differentiate between pure and more complex forms (Figure 4). Atrophy of the 
brainstem is seen more often in coding triplet disorders. Also among ARCA atrophy of the 
cerebellum is seen in variable degrees (6;81). In recessive or isolated cases it is helpful to use 
the biomarkers which are cheap and easy to perform. It is of valuable help also to reconsider 
the diagnosis after a while and sometimes do some of the investigations again, because 
clinical signs and symptoms can be more prominent in later disease stages.  
In all ARCA and sporadic progressive ataxia we recommend taking biomarkers, MRI of the 
cerebrum/medulla and neurography as the first diagnostic workup. If the biomarkers are 
negative it is today recommended to test for expansions in the FRDA gene first. Worldwide it 
is recommended to test for SCA1,2,3,6 and 7 among ADCA subjects and in addition perform 
supplementary investigations in order to exclude secondary causes (6;9). Since few of the 
well-known ADCA genotypes are found in Norway it can be argued not to test for these if no 
brainstem symptoms are found, if the brainstem has normal appearance on brain MRI and if 
no family members affected are from outside Norway. On the other hand these tests are easy 
to perform, cheap compared with other genetic tests and may give a few families an exact 
diagnosis which is important for follow up, prognosis and probably for therapy in the future.  
 
Many different medication and treatment options have been tried in order to reduce symptoms 
and to stop the neurodegeneration, but with little or no effect (11;105;106;108). 
The main goal for designing treatment is to target the mechanism underlying the disorder. 
Despite the increased knowledge in genetics and the pathophysiology we still have too little 
knowledge about the pathways and why cells start to degenerate. The only medications shown 
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to have effect are vitamin E in AVED due to mutations in a vitamin E transport protein 
(53;57) and mild dose-dependent improvement in neurological function and reduction in 
cardiomyopathy in children with Friedreich’s ataxia using Idebenone (105;109-111). We 
started vitamin E supplementation in the patient published in Paper 2, but she was diagnosed 
very late and little improvement is seen after medication was started. It is of great importance 
to start as early as possible in AVED subjects and therefore patients with progressive sensory 
and/or cerebellar ataxia should to be screened for vitamin E deficiency. Antiepileptic drugs 
are recommended in episodic ataxia (Azetolamide as the first choice), but medications only 
reduce attacks not the neurodegeneration (10). The treatment of hereditary ataxias today is 
therefore primarily supportive. Physical methods such as training (112), different walk-
assistants (cane, walker, adding weights to the wrists) and education can in some degree 
compensate for the incoordination. Speech therapists are also key partners, because of the 
frequent problems with dysphagia and dysarthria. Last a good collaboration with 
rehabilitation institutions is important for follow up of these patients. 
There is a need for strategies to handle referred patients with hereditary ataxia. Before we 
started our study there was no follow up strategies for these patients in Norway, there were no 
guidance for training, physiotherapy or how to cope with all the problems and symptoms. 
Therefore Figure 15 summarizes our advices based on our experiences with these disorders. 
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Figure 14. Flowchart for approach to the patient with cerebellar ataxia 
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Figure 15. An illustration of how caretaking of hereditary ataxia patients can be practiced in 
Norway 
 
  
Modified after Anne Kjersti Erichsen, Hereditary spastic paraplegia in Norway, thesis 2009 
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Ethical aspects 
The project has been approved by the Regional Ethical committee (Ethical agreement no 
129/04011 Helse sørøst). As the project has been expanding during the past years, Chantal 
Tallaksen submitted a new protocol to REK 2010, including an enquiry for the establishment 
of a research biobank, which was accepted. At the Department of Medical Genetics, OUH 
they have a protocol for dealing with incidental findings of clinical relevance, including 
genetic counseling and an ethical review board. All patients have given informed written 
consent. 
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Conclusions 
1. Prevalence of hereditary ataxias was estimated at 6.54/100 000, ADCA was 4.27/100 
000 and ARCA at 2.27/100 000. 
2. One subject in our material was diagnosed with AVED, having a Friedreich’s ataxia 
phenotype. 
3. A novel truly disease-causing mutation in the PRKCG gene, in exon 5, was discovered 
in the two first Norwegian SCA14 families with a slowly progressive ataxia.  
4. A family with a late onset autosomal dominant ataxia was linked to a new locus on 
chromosome 10. 
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Further perspectives 
Chantal Tallaksen and her research group have included families and patients in the database 
since 2002 and many families still not have exact diagnoses. It is likely to assume that we 
have new genotypes in the Norwegian population due to results from this thesis and further 
research on these families is needed. In Paper 4 we published a new locus and another family, 
not yet published is also linked to another new locus. Exom-sequencing is currently started in 
order to find the genes in these families.  
The database has expanded every year with more families and patients. In the following years 
this database will be a research platform for exploring new phenotypes especially among 
subgroups such as; spastic ARCA, episodic ADCA and pure, late onset ADCA. The new 
technological developments with exom sequencing and Next-Generation-Sequencing have 
revolutionized genetic research the past years improving the possibilities to find the gene and 
reducing the often limiting step; time. In a short time the next limiting factor; money, will also 
be improved as costs are rapidly diminishing. We have now a great opportunity with selected 
phenotypes included in the database to find new genes with newer and faster methods. 
This database will also help us to understand the clinical aspects of these disorders and 
hopefully in the future include patients in clinical medication trials. Monogenetic disorders 
are excellent models for understanding genes and their role in cellular and intracellular 
pathways. In collaboration with Joel Glover at the Stem Cell Center at Rikshospitalet we have 
started a project on SCA14. Induced pluripotent stem cells will be cultured from fibroblast 
cells from patients with SCA14 with the aim to generate human neurons. This provides us 
with exceptional opportunities for developing an in-vitro model for this disorder and trough 
this model provide better understanding of the ongoing neurodegenerative processes inside 
the Purkinje cells.  
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Collaboration 
The European network for spinocerebellar degenerative disorders (SPATAX) was established 
in 2000 and includes clinicians, neurologists, basic scientists, geneticists, pathologists and 
patients’ associations. A neurogenetic platform was recently established at Oslo University 
Hospital. This collaboration is an important network in order to discuss new methods, to find 
new phenotypes/genotypes, to start screening projects and to be kept updated in diagnostic 
and treatment options. 
The laboratory work has been achieved in collaboration with European research centers, 
mostly INSERM at the Salpêtrière Hospital in Paris and Oslo University Hospital, Ullevål, 
Department of Medical Genetic. 
Moreover, the European collaboration has been extended to the ASG (Ataxia Study Group) 
which comprises partners from most European countries.  
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Appendix 1 
Autosomal dominant cerebellar ataxias  
SCA1 (MIM ID #164400)  
SCA1 was the first dominant genetic form discovered (1993). It is caused by CAG repeat expansions. Repeat 
numbers greater than 39 is mostly pathogenic. Symptoms can start in all ages, but most often in the mid 30’s. 
Brain MRI reveals atrophy of the cerebellum and pons. The first symptoms are usually unsteadiness and 
coordination problems. Pyramidal signs are often seen and the phenotype can be ALS-like.  
SCA2 (MIM ID #183090)  
SCA2 was first described in families from Cuba and the gene was found in 1993. This form is also caused by a 
CAG repeat expansion. Repeat numbers greater than 35 is pathogenic. Common features are slowness and 
ophtalmoplegia of eye movements, neuropathy, reduced reflexes and memory loss in addition to the cerebellar 
ataxia. Brainstem atrophy with thinning of the pons is often seen on brain MRI.  
SCA3 (MIM ID#109150)- 
SCA3 is also known as Machado-Joseph disease (MJD). It is caused by a repeat expansion greater than 67 
repetitions. Symptoms beside ataxia include tremor, rigidity, myokymias and neuropathy. SCA3 is the most 
common dominant ataxia in many parts of the world and especially in Portugal. 
SCA5 (MIM ID#600223)  
This form of ataxia was found in one branch of Abraham Lincoln’s family, known as Lincoln’s ataxia. It is 
caused by missense mutations in the SPTBN2 gene. SCA5 has onset in all ages, but most often in young ages. 
The disease progress slowly. SCA5 is described as “pure”. 
SCA6 (MIM ID#183086) 
SCA6 has mutations in the same gene as EA2 and hemiplegic migraine, but the mutation is caused by CAG 
repeats. SCA6 may initially present as an EA2-episodic disorder and many patients have migraine in addition to 
the cerebellar symptoms and signs.  Acetazolamide (Diamox) can give symptom relief. It is often described as a 
relatively pure cerebellar disorder. 
SCA7 (MIM ID#164500) 
SCA7 is what Harding described as ADCAII, with retinopathy. This neurodegenerative disorder is caused by 
repeat expansions greater than 36. Anticipation is reported giving an aggressive juvenile form.  
SCA8 (MIM ID#608768) 
SCA8 gives poor coordination of the extremities, mostly the lower extremities, poor coordination of gait and 
speech. Spasticity is reported. Many patients with CAG/TAG expansion in one allele do not develop the 
disorder, due to factors not well understood. It is reduced penetrance in SCA8. An expansion larger than 71 can 
give SCA8. 
SCA10 (MIM ID#603515) 
SCA10 is a slowly progressive ataxia described in Mexico and Brazil. In addition to the cerebellar ataxia patients 
may develop epilepsy, weakness, and loss of sensation. SCA10 is caused by an ATTCT repeat expansion greater 
than 850 in the intron of the ataxin10 gene.  
SCA11 (MIM ID#604432) 
This is a seldom form, relatively pure late onset cerebellar ataxia caused by mutations in the TTBK2 gene. Some 
patients have pyramidal signs. 
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SCA12 (MIM ID#604326) 
SCA12 is associated with tremor. Tremor can be the first symptom and later the ataxia is more prominent. In 
addition Parkinson-like feature may also occur and exaggerated tendon reflexes and loss of sensation can be 
seen. SCA12 is caused by a CAG repeat expansion. If one allele has 51-78 repeats the subjects will develop 
SCA12.  
SCA13 (MIM ID#603259) 
SCA13 is often early onset, progressive ataxia. Cognitive decline is often seen, especially among those with 
early onset. Pyramidal signs are also reported in some subjects. Missense mutations in a potassium channel gene. 
SCA14 (MIM ID#605361)  
SCA14 is found in the Norwegian ataxia population, but is rare. SCA14 is characterized by a slowly progressive 
ataxia with often additional pyramidal signs. Many patients are described with myoclonus and cognitive decline, 
but these findings are not seen among the Norwegian patients.  
SCA15/16 606658) 
This disorder was first described as two different SCA with loci close to each other. A huge deletion in the 
ITPR1 gene in ataxic mice was found (66) and explained both the SCA15 and 16 families. Missense mutations in 
the gene do explain the genotype in some families, but most families published have huge deletions in the gene. 
This ataxia appears to be a slowly progressive form of ataxia from early childhood.  
SCA17 (MIM ID#607136) 
SCA17 is associated with chorea, dystonia, psychiatric symptoms, memory loss and ataxia. They may also have 
Parkinson-like features. This is a CAG repeat disorder. If one copy of the gene has 43-48 repeats, the individual 
might develop the disorder. If one copy of the gene has 49 or more repeats the individual will develop SCA17. 
SCA23 (MIM ID#610245) 
SCA23 has been described in Dutch families. Symptoms begin in the 40’s and 50’s. In addition to typical 
symptoms of ataxia, there are pronounced problems with eye movements. The PDYN gene for this SCA is 
recently found. 
SCA27 (MIM ID#609307) 
SCA27 was originally described in a Dutch family. SCA27 is caused by mutations in FGF14 gene. This SCA is 
found in Norway (114). Mental impairment, cerebellar dysfunction, neuropathy, tremor exaggerated by physical 
exercise and stress and in some patients aggressive outbursts and orofacial dyskinesia are reported. 
SCA28 (MIM ID#610246) 
SCA28 has an early onset ataxia. It was first described in Italian and German families first. This is probably a 
seldom dominant ataxia due to an occurrence study newly performed. The phenotype is an early onset, slowly 
progressive relative pure ataxia, but with pyramidal signs in many of the reported patients. SCA28 is caused by 
sequence changes in AFG3L2 gene.  
SCA31 (MIM ID#117210) 
This is a relatively pure cerebellar ataxia with late onset caused by an insertion of a penta-nucleotid repetition. In 
a few patients hearing loss is reported. The SCA4 locus is very close to this locus, but the phenotypes is 
described different. Few families are reported. 
Episodic ataxias 
EA1 (MIM ID #160120) 
This type of ataxia is caused by sequence changes in the gene KCNA1. This gene is a potassium channel. 
Symptoms often begin in early life. Episodes of ataxia may last from seconds to minutes, but rarely hours.  
During the attacks patients have cerebellar symptoms with ataxia, double vision, nausea and difficulties in 
speaking, but also tightening of muscles/myotonia and headache are observed. In between episodes, patients may 
experience myokymia. 
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EA2 (MIM ID#108500) 
This type of ataxia is caused by sequence changes in the gene CACNA1A. This is a Calcium channel gene. The 
symptoms during the attacks can be similar to EA1, but last longer, often for hours. Symptoms from the 
cerebellum with unsteady gait and nystagmus can be seen in between attacks and especially with longer disease 
duration. Episodes are often triggered by stress, caffeine, alcohol and physical exercise. 
EA5 (MIM ID#613855) 
This EA is caused by mutations in the CACNB gene, which also is an ion channel gene. This EA is described in a 
few families with ataxia and also in families with epilepsy. 
EA6 (MIM ID#612656) 
EA6 is caused by mutations in the SLC1A gene. This EA is seldom, only few families are published with 
associated migraine, hemiplegic features and with ataxia symptoms also between attacks. 
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Appendix 2 
 
Autosomal recessive cerebellar ataxias 
Friedreich's ataxia (MIM ID #229300)  
This is a neurodegenerative disorder, mainly affecting the spinocerebellar tracts, dorsal columns and pyramidal 
tracts. Cerebellar atrophy is a late finding. Age of onset is in the first and second decades of life, but late age of 
onset is also reported. Weakness of the extremities and loss of sensation become more prominent as the disease 
progresses. Skeletal deformities, including scoliosis, heart problems and diabetes mellitus are commonly 
features. Most individuals with FRDA have repeat expansions in both alleles in the Frataxin gene, but  2% of the 
individuals are reported to have a combination of a repeat expansion in one gene and a missense mutation in the 
other allele. Lack of vibration sense and joint position/sensory ataxia is the main feature. Decreased reflexes are 
seen, but with positive Babinski sign. Skeletal deformities, heart problems and diabetes mellitus are also 
commonly seen.  
Ataxia telangiectasia (MIN ID#208900) 
Ataxia telangiectasia is an early onset recessive ataxia with a high prevalence in Norway due to the founder 
mutation in the county Hedmark, the mutation is called; Rendalen mutation. A-T is the second most frequent 
ARCA described worldwide and the most frequent form in Norway. The disorder is characterized by cerebellar 
ataxia, oculomotor apraxia, conjuctival telangiectasia, immune system defects and an increased risk for some 
types of cancers. Movement problems are commonly seen such as; choreatetosis and dystonia. The ataxia is 
often the first sign and telangiectasia is a later sign. Biomarkers in blood are; elevated α-foetoprotein and low 
levels of immunoglobulin. α -foetoprotein increases with age, due to mechanisms not well understood 
(50;51;115). 
Ataxia with vitamin E deficiency (AVED) (MIM ID #277460)  
Ataxia with vitamin E deficiency (AVED) manifests most often in childhood or early teens with poor balance 
when walking with loss of proprioception, cerebellar signs, dysarthria and areflexia. AVED may present as a 
FRDA like disorder. Some patients can have dystonia, head titubation (see article 2) retinopathy, cognitive 
symptoms and psychiatric symptoms. If not treated patients become wheelchair bound as a result of the 
neurodegeneration.  A FRDA-like ataxia and very low serum vitamin E in the absence of fat malabsorbation are 
the diagnostic criteria. Genetic testing is available and recommended. Cardiomyopathy is not common in AVED. 
Treatment with vitamin E supplement at least 800 mg daily is recommended as early as possible in order to stop 
the neurodegeneration. It is recommended to screen all patients with recessive and sporadic ataxia for vitamin E 
deficiency, because this is the only ataxia with a treatment. 
Spinocerebellar ataxia autosomal recessive 1/ Ataxia with oculomotor apraxia type 2 (AOA2)-(MIM ID 
#606002) 
SCAR 1 is also called AOA2. This is an inherited ataxia with onset usually before 20 years. Patients often have 
problems to initiate eye movements, therefore given the descriptive name; oculomotor apraxia. α-foetoprotein in 
their blood is often elevated (not understood why) and can be used as a biomarker in this recessive disorder. 
Dystonia, chorea and neuropathy in addition to the ataxia are commonly seen. Two mutations in the Senetaxin 
gene are the genetic reason to this ataxia (74). 
Ataxia with oculomotor apraxia type 1 (AOA1) (MIM ID #208920) 
This form often have earlier onset than AOA2. The clinical feature can be similar to AOA2/SCAR1, but in 
addition often movement problems are seen (chorea and dystonia) and neuropathy is prominent. There are no 
good biomarkers for this disorder, but elevated levels of cholesterol and low levels of an albumin may be found.  
Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) (MIN ID #270550) 
Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is characterized by early-onset spastic 
ataxia in addition to distal sensorimotor neuropathy and nystagmus. Hypermyelinated fibers which radiate from 
the edges of the optic fundus in the retina are seen in some families from Canada, but not in the French ARSACS 
families. This form is caused by mutations in the SACS gene. 
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DIAGNOSTIC FORM  for SPINOCEREBELLAR DEGENERATION  
(ATAXIA AND/OR SPASTIC PARAPARESIS) 
Date: _________________________ID-number: _______________________________ 
Center : _______________________Examinator: ______________________________ 
Proband:  yes  no 
Age at examination :_____________Sex:  M  F Geographical origin: __________________ 
Initial examination yes  no  Follow-up number: _________________________ 
Age at death: ___________________Cause: ___________________________________ 
A. FAMILIAL HISTORY (add pedigree) 
- Spastic paraparesis and or ataxia in the family yes   no 
- Other familial disease     yes   no  name: ____________ 
- Consanguinity     yes   no  precise: __________ 
B. AGE AT ONSET OF THE FIRST SIGN:__________________________________
C. PRESENTING SIGNS 
- Motor development  normal   delayed  describe: 
- Learning abilities  normal   delayed  describe:  
Signs at onset Yes No At Age 
                      - Unsteadiness  
                      - Dysarthria 
                      - Stiff legs 
                      - Cramps  
                      - Medical exam 
                      - Pain 
                      - Other (describe) 
D. PREDOMINANT SIGNS at present examination 
SPASTICITY CEREBELLAR ATAXIA 
None Mild Moderate Severe None Mild Moderate Severe
Upper limbs        
Lower limbs *        
Gait        
Dysarthria        
*at rest for spasticity and knee-heel for cerebellar ataxia 
E. DISABILITY STAGE      At age       
0: no functional handicap 
1: no functional handicap but signs at examination  
2: mild, able to run, walking unlimited 
3: moderate,unable to run, limited walking without aid
4: severe,walking with one stick 
5. walking with two sticks 
6: unable to walk, requiring wheelchair 
7: confined to bed 
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F. OTHER CLINICAL SIGNS 
1. Reflexes          Normal     Enhanced       Very brisk    Diminished     Absent Clonus 
Jaw Jerk               
Biceps                            
Finger flexor                           
Patellar                           
Adductor                           
Achilles                           
Hoffmann’s sign absent   present  
Plantar reflex      flexor  indifferent  unilateral extensor  bilateral extensor 
2. Motor deficit None  Mild  Moderate  Severe 
UL prox                        
UL distal                        
LL prox                        
LL distal                       
Facial palsy/atrophy                     
3. Muscle wasting None  Mild  Moderate  Severe 
UL prox                       
UL distal                       
LL prox                        
LL distal                        
4. Fasciculations yes  no  localisation:_____________ 
5. Sensory deficit
- Vibration sense at ankles:  abolished   <5 seconds  5-10 sec  >11 seconds (normal) 
- Superficial sensory loss yes  no   Underlign:  Touch  Prick  Cold 
6. Skeletal abnormalities
None Mild Moderate Severe  Other: 
- Scoliosis                     
- Pes cavus              
7. Facial dysmorphia  yes    no   describe: 
8. Sphincter and sexual disturbances
None  Mild  Moderate  Severe
Urinary urgency                       
Urinary incontinence                        
Urinary retention                      
Anal incontinence                        
Impaired sexual function                     
Early menopause     yes    no       age:  _______________________ 
9. Extra-pyramidal symptoms None Mild Moderate    Severe Site
- Rest/postural/action tremor                    _______________________ 
- Chorea                  _______________________ 
- Dystonia                _______________________ 
- Myoclonus                _______________________ 
- Hypokinesia              _______________________ 
- Rigidity               _______________________ 
                  SPATAX  2003 
3
10. Ophthalmological signs 
*Observation     Yes  No 
- Diplopia      
- Ptosis         
- Eye lid retraction (bulging eyes)   
- Diminished visual acuity     age at onset: _____________________
*Movement:
- Nystagmus        describe: ________________________
- Saccadic pursuit      describe: ______________________________ 
- Slow saccades     
- Ocular motor apraxia    
- Supranuclear ophthalmoplegia    describe: ______________________________
- Nuclear ophthalmoplegia     describe: ______________________________
*Eye fundus 
- Abnormal fundii     
 Optic atrophy   Retinis Pigmentosa   Other : ___________
11. Mental status
- Intellectual deterioration    onset/type: ________________________
- Mental retardation     onset and degree: ___________________
- Psychiatric symptoms    describe: __________________________
- Depression     
12. Other signs
Yes No 
- Dysphagia      describe: ____________ onset: ____________
 Graduation:  Mild   Moderate  Severe
- Skin problems     describe: 
- Hearing impairment     describe: 
- Epilepsia      type and onset: 
13. Other medical complaints:
G. SCORES OF CLINICAL EVALUATIONS  
Cerebellar gait score (Annex 1a):  ____________ 
Adiadocho-score (Annex 1b): ____________  
Dysarthria score (Annex 1c):  ____________ 
Ashworth score (Annex 2a):   ____________ 
Ambulatory score (Annex 2b): ____________ 
PATA test (Annex 3):   ____________ 
H. DIAGNOSTIC CONCLUSION 
Cerebellar ataxia  Spastic paraparesis    
- AR / AD / ISOLATED/ X-LINKED  - AR / AD / ISOLATED/ X-LINKED 
- Pure / complex     - Pure / complex
1. Definitely affected    1.  Definitely affected
2.Probably affected    2.  Probably affected
(Only dysarthria)     (enhanced or very brisk LL reflexes ± Babinski)
3.Possibly affected     3.  Possibly affected 
(Only mild gait ataxia)    (enhanced reflexes in LL)  
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I. MOLECULAR DIAGNOSIS:  
J. INVESTIGATIONS   
not done  normal  abnormal describe  
1. VLCFA                       _________ 
2. D-foetoprotein                     _________  
3. Cholesterol                       _________ 
4. Serum protein electrophoresis                  _________ 
5. Cerebral MRI                     _________  
6. Medullar MRI                      _________  
7. EMG + NCV UL                      _________  
8. EMG + NCV LL                      _________  
9. VEP                       _________  
10. AEP                      _________  
11. MEP                       _________  
12. SEP                       _________  
13. Muscle biopsy                      _________ 
14. Skin biopsy                      _________ 
15. ERG                              _________ 
16. Fundus examination                      _________  
17. Neuropsychological exam                    _________  
18. Urodynamics                      _________  
19. Urine density                   _________ 
20. Vitamin E                    _________ 
21. Apolipoprotein A , B                  _________ 
K. STORED MATERIAL   
Yes  No
DNA       
Immortalized cell lines     
Muscle tissue      
Skin biopsy      
Nerve biopsy      
Other:
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ANNEXES 
ANNEX 1a: Cerebellar gait score (Standing capacities, eyes open) 
0  Normal: able to stand on one foot more than 10 s. 
1  Able to stand with feet together, but no longer able to stand on one foot more than 10 s. 
2  Able to stand with feet together, but no longer able to stand with feet on tandem position. 
3  No longer able to stand with feet together, but able to stand in natural position without support, 
with no or moderate sway.  
4  Standing in natural position without support, with considerable sway and considerable 
corrections.  
5  Standing in natural position with unilateral support 
6  Standing in natural position with bilateral support 
7  Unable to stand at all  
ANNEX 1b: Adiadocho-score 
In sitting position, count the number of alternate movements of the dominante hand. Count only dorsal 
touch during 10 seconds (normal: 15-20) 
ANNEX 2a: Modified Ashworth Scale
0  No increase in muscle tone. 
1   Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at 
the end range of motion when the part is moved in flexion or extension/adduction, etc or 
followed by minimal resistance throughout the remainder (less than half) of the range of 
motion.
2  More marked increase in muscle tone through most of the range of motion, but the affected part 
is easily moved. 
3  Considerable increase in muscle tone, passive movement is difficult. 
4   Affected part is rigid in flexion or extension (abduction or adduction, etc.). 
ANNEX 2b: Ambulatory Score (0 – 10) Add A+B 
Number of meters in 5 seconds
A) Without aid  B) With aid 
0 > 5 m    0  > 5 m  
1 t 4 m     1  t 4 m   
2 t 3 m     2  t 3 m  
3 t 2 m     3  t 2 m  
4 t 1 m     4  t 1 m  
5  0 m     5  0 m  
ANNEX 3: PATA test: dysarthria evaluation 
Count the number of repetitions of the “Pa Ta” syllables pronounced during 10 seconds. 
Rater: ____________________________date: ______________patient:_______________________ 
 1 
Scale for the assessment and rating of ataxia (SARA) 
 
1) Gait 
Proband is asked (1) to walk at a safe distance parallel to 
a wall including a half-turn (turn around to face the 
opposite direction of gait) and (2) to walk in tandem 
(heels to toes) without support.  
 
 
 
0 Normal, no difficulties in walking, turning and  
       walking tandem (up to one misstep allowed) 
   1     Slight difficulties, only visible when walking 10  
          consecutive steps in tandem 
   2     Clearly abnormal, tandem walking >10 steps not      
          possible 
   3     Considerable staggering, difficulties in half-turn, but  
          without support 
   4    Marked staggering, intermittent support of the wall  
          required 
   5     Severe staggering, permanent support of one stick or 
          light support by one arm required 
6 Walking > 10 m only with strong support (two  
        special sticks or stroller or accompanying person)  
7 Walking < 10 m only with strong support (two  
        special sticks or stroller or accompanying person)  
   8     Unable to walk, even supported 
2) Stance 
Proband is asked to stand (1) in natural position, (2) with 
feet together in parallel (big toes touching each other) and 
(3) in tandem (both feet on one line, no space between 
heel and toe). Proband does not wear shoes, eyes are 
open. For each condition, three trials are allowed. Best 
trial is rated. 
 
   0     Normal, able to stand in tandem for > 10 s 
   1     Able to stand with feet together without sway, but  
          not in tandem for > 10s 
   2     Able to stand with feet together for > 10 s, but only  
         with sway 
   3     Able to stand for > 10 s without support in natural  
         position, but not with feet together 
   4     Able to stand for >10 s in natural position only with  
          intermittent support 
   5     Able to stand >10 s in natural position only with  
          constant support of one arm  
   6     Unable to stand for >10 s even with constant support  
          of one arm 
 
  Score    Score  
3) Sitting 
Proband is asked to sit on an examination bed without 
support of feet, eyes open and arms outstretched to the 
front. 
 
   0     Normal, no difficulties sitting >10 sec 
   1     Slight difficulties, intermittent sway 
2 Constant sway, but able to sit > 10 s without support 
   3     Able to sit for > 10 s only with intermittent support 
   4     Unable to sit for >10 s without continuous support 
 
4) Speech disturbance 
Speech is assessed during normal conversation. 
 
 
 
   0     Normal 
   1     Suggestion of speech disturbance 
   2     Impaired speech, but easy to understand 
   3     Occasional words difficult to understand 
   4     Many words difficult to understand 
   5     Only single words understandable 
   6     Speech unintelligible / anarthria 
  Score     Score  
Rater: ____________________________date: ______________patient:_______________________ 
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5) Finger chase  
Rated separately for each side 
Proband sits comfortably. If necessary, support of feet 
and trunk is allowed. Examiner sits in front of proband 
and performs 5 consecutive sudden and fast pointing 
movements in unpredictable directions in a frontal plane, 
at about 50 % of proband´s reach. Movements have an 
amplitude of 30 cm and a frequency of 1 movement 
every 2 s. Proband is asked to follow the movements 
with his index finger, as fast and precisely as possible. 
Average performance of last 3 movements is rated.  
 
   0     No dysmetria  
   1     Dysmetria, under/ overshooting target <5 cm 
   2     Dysmetria, under/ overshooting target < 15 cm  
   3     Dysmetria, under/ overshooting target > 15 cm 
   4     Unable to perform 5 pointing movements 
 
6) Nose-finger test  
Rated separately for each side 
Proband sits comfortably. If necessary, support of feet 
and trunk is allowed. Proband is asked to point repeatedly 
with his index finger from his nose to examiner’s finger 
which is in front of the proband at about 90 % of 
proband’s reach. Movements are performed at moderate 
speed. Average performance of movements is rated 
according to the amplitude of the kinetic tremor.  
 
 
 
   0     No tremor  
   1     Tremor with an amplitude < 2 cm 
   2     Tremor with an amplitude < 5 cm  
   3     Tremor with an amplitude > 5 cm  
   4     Unable to perform 5 pointing movements  
Score Right Left Score Right Left 
mean of both sides (R+L)/2  mean of both sides (R+L)/2  
7) Fast alternating hand movements  
Rated separately for each side  
Proband sits comfortably. If necessary, support of feet 
and trunk is allowed. Proband is asked to perform 10 
cycles of repetitive alternation of pro- and supinations of 
the hand on his/her thigh as fast and as precise as 
possible. Movement is demonstrated by examiner at a 
speed of approx. 10 cycles within 7 s. Exact times for 
movement execution have to be taken. 
 
   0     Normal, no irregularities (performs <10s) 
   1     Slightly irregular (performs <10s) 
   2     Clearly irregular, single movements difficult  
          to distinguish or relevant interruptions, but   
          performs <10s 
   3    Very irregular, single movements difficult  
          to distinguish or relevant interruptions,  
          performs >10s 
   4     Unable to complete 10 cycles 
  
8) Heel-shin slide  
Rated separately for each side 
Proband lies on examination bed, without sight of his 
legs. Proband is asked to lift one leg, point with the heel 
to the opposite knee, slide down along the shin to the 
ankle, and lay the leg back on the examination bed. The 
task is performed 3 times. Slide-down movements should 
be performed within 1 s. If proband slides down without 
contact to shin in all three trials, rate 4.  
 
   0     Normal 
   1     Slightly abnormal, contact to shin maintained  
2 Clearly abnormal, goes off shin up to 3 times   
       during 3 cycles 
3 Severely abnormal, goes off shin 4 or more times  
       during 3 cycles 
   4     Unable to perform the task 
 
  Score Right Left   Score Right Left 
  mean of both sides (R+L)/2    mean of both sides (R+L) / 2  
I

II

III

IV

